Reporters and editors from the Pink Sheet, MedTech Insight and HBW Insight discuss the first 100 days of US Food and Drug Administration Commissioner Robert Califf’s second stint as FDA Commissioner, including goals, accomplishments, trials and tribulations across the drug, device and health and wellness sectors and how ongoing crises like the infant formula shortage could affect them. They also consider the potential for lasting change at the agency going forward.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?